




# Efflux Impacts Intracellular Accumulation Only in Actively Growing Bacterial Cells

Emily E. Whittle,<sup>a</sup> Helen E. McNeil,<sup>a</sup> Eleftheria Trampari,<sup>b</sup> Mark Webber,<sup>b</sup> Tim W. Overton,<sup>c</sup>  Jessica M. A. Blair<sup>a</sup>

<sup>a</sup>College of Medical and Dental Sciences, Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom

<sup>b</sup>Quadram Institute Bioscience, Norwich, United Kingdom

<sup>c</sup>School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom

**ABSTRACT** For antibiotics with intracellular targets, effective treatment of bacterial infections requires the drug to accumulate to a high concentration inside cells. Bacteria produce a complex cell envelope and possess drug export efflux pumps to limit drug accumulation inside cells. Decreasing cell envelope permeability and increasing efflux pump activity can reduce intracellular accumulation of antibiotics and are commonly seen in antibiotic-resistant strains. Here, we show that the balance between influx and efflux differs depending on bacterial growth phase in Gram-negative bacteria. Accumulation of the fluorescent compound ethidium bromide (EtBr) was measured in *Salmonella enterica* serovar Typhimurium SL1344 (wild type) and efflux deficient ( $\Delta$ acrB) strains during growth. In SL1344, EtBr accumulation remained low, regardless of growth phase, and did not correlate with *acrAB* transcription. EtBr accumulation in the  $\Delta$ acrB strains was high in exponential phase but dropped sharply later in growth, with no significant difference from that in SL1344 in stationary phase. Low EtBr accumulation in stationary phase was not due to the upregulation of other efflux pumps but instead was due to decreased permeability of the envelope in stationary phase. Transcriptome sequencing (RNA-seq) identified changes in expression of several pathways that remodel the envelope in stationary phase, leading to lower permeability.

**IMPORTANCE** This study shows that efflux is important for maintaining low intracellular accumulation only in actively growing cells and that envelope permeability is the predominant factor in stationary-phase cells. This conclusion means that (i) antibiotics with intracellular targets may be less effective in complex infections with non-growing or slow-growing bacteria, where intracellular accumulation may be low; (ii) efflux inhibitors may be successful in potentiating the activity of existing antibiotics, but potentially only for bacterial infections where cells are actively growing; and (iii) the remodeling of the cell envelope prior to stationary phase could provide novel drug targets.

**KEYWORDS** antibiotic resistance, efflux pumps, membrane permeability

Antibiotic treatment failure in clinical infections is increasingly common due to the rise in multidrug resistant (MDR) Gram-negative bacteria. Infections with Gram-negative organisms are particularly difficult to treat due to their impermeable outer membranes and efflux pumps, which actively export antibiotic molecules out of the bacterial cell. Successful treatment relies on high concentrations of antibiotic accumulating within bacterial cells, which is a function of antibiotic influx and the rate of antibiotic efflux (1).

Small hydrophilic antibiotics such as  $\beta$ -lactams enter a Gram-negative bacterial cell through membrane pores called porins. The major porins of *Enterobacteriaceae* are OmpF and OmpC (2). Downregulation of porin genes contributes to antibiotic resistance by preventing

**Citation** Whittle EE, McNeil HE, Trampari E, Webber M, Overton TW, Blair JMA. 2021. Efflux impacts intracellular accumulation only in actively growing bacterial cells. *mBio* 12: e02608-21. <https://doi.org/10.1128/mBio.02608-21>.

**Editor** Gerard D. Wright, McMaster University

**Copyright** © 2021 Whittle et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Jessica M. A. Blair, [J.M.A.Blair@bham.ac.uk](mailto:J.M.A.Blair@bham.ac.uk).

**Received** 2 September 2021

**Accepted** 8 September 2021

**Published** 12 October 2021

antibiotics from entering the cell (3). In addition, mutations in the porin protein which change the channel diameter (4, 5) or the electric field inside the porin can block translocation of drugs across the membrane (5).

Some drugs can enter Gram-negative cells through the lipid outer and inner membranes via “self-promoted uptake.” This mechanism has been described for EDTA, polymyxin B, colistin and other cationic antimicrobial peptides (CAMPs), and aminoglycoside antibiotics (6–8). The chelator EDTA acts as a permeabilizer by displacing and chelating the cations ( $Mg^{2+}$  or  $Ca^{2+}$ ) that are essential for the stability of lipopolysaccharide (LPS) and the outer membrane (OM) (6, 9). CAMPs interact with anionic groups on lipid A, breaching the outer membrane, and cause poration in the inner membrane, leading to bacterial death.

*Enterobacteriaceae* contain efflux pumps from 6 classes. Major facilitator superfamily (MFS), small multidrug resistance family (SMR), multidrug and toxic compound extrusion (MATE), resistance-nodulation-division (RND), and the recently described proteobacterial antimicrobial compound efflux family (PACE) pumps (10) utilize the proton motive force for export of molecules such as antibiotics, and ABC (ATP binding cassette) pumps utilize ATP hydrolysis. RND pumps are commonly upregulated in clinical isolates and can contribute to resistance to a number of antibiotic classes, as well as dyes, detergents, and biocides (11). The best-described RND pump is AcrAB-TolC, found in *Salmonella enterica* serovar Typhimurium and *Escherichia coli*. As efflux pumps underpin antibiotic resistance in essentially all bacteria of clinical and veterinary importance (12, 13), there is ongoing active research into the development of efflux inhibitors to potentiate the action of existing antibiotics.


Previous studies undertaken with cells in exponential growth phase have highlighted the importance of efflux pumps in minimizing intracellular drug accumulation (14–17). However, transcription of *acrAB* is growth phase dependent, with a peak in mid-exponential phase, which drops as cells enter stationary phase (18). The importance of AcrAB-TolC in bacterial cells in stationary phase which are slow growing or nongrowing is not known. However, it has been suggested that whereas survival of exponential-phase *E. coli* following treatment with the anionic detergent sodium dodecyl sulfate (SDS) is dependent on efflux, stationary-phase cell survival is efflux independent and is instead mediated by decreased permeability of the bacterial cell envelope, directed by the stationary-phase sigma factor RpoS (19). Little is known about the balance between influx and efflux in different growth phases and how this may relate to different growth states that may occur in an infection.

Previous studies have shown that the *E. coli* envelope changes in stationary phase compared to logarithmic growth, and it is possible that this could alter antibiotic influx in nongrowing bacterial cells. Outer membrane changes include a decrease in the overall concentration of membrane proteins (20) and an increase in lipoprotein cross-linked to peptidoglycan (21, 22) to strengthen the outer barrier. In the inner membrane, the composition of fatty acids changes with a decrease in monounsaturated fatty acids (23) and an increase in cyclopropane fatty acids, catalyzed by Cfa (24). Increased layers of peptidoglycan have also been observed in stationary phase (25).

Using a combination of fluorescent drug accumulation assays (17) and measurement of efflux gene transcription in wild-type and efflux mutant strains, we assessed the importance of the balance between influx and efflux in different growth phases in Gram-negative bacteria, using the model organism *Salmonella enterica* serovar Typhimurium. We also used RNA sequencing (RNA-seq) to measure the global transcriptome as bacteria enter stationary phase and correlate transcriptomic changes with biochemical and physiological changes in the cell envelope that lead to alterations in permeability.

## RESULTS

**Intracellular EtBr accumulation by *S. Typhimurium* is independent of growth phase-dependent *acrAB* transcription.** Using a recently developed flow cytometry method (17), both the intracellular accumulation of the fluorescent dye ethidium bromide



**FIG 1** Ethidium bromide accumulation and *acrAB* expression in single cells of *S. Typhimurium* SL1344 across the growth phase. Cell number per milliliter was measured in each sample (black lines; numbers indicated on the right y axis). Pink bars indicate median ethidium bromide fluorescence per cell (relating to left red y axis), and dashed lines with green circles show *acrAB* expression (median GFP fluorescence per cell from the reporter; left green y axis). All data points are median values from measurements of 10,000 single cells of SL1344. Error bars indicate standard errors of the means (SEM).


(EtBr) and the transcription of *acrAB* (via a promoter-green fluorescent protein [GFP] fusion) were measured in parallel in single cells of *Salmonella* grown in drug-free medium. Samples were taken hourly during batch culture before EtBr was added to the sample immediately prior to flow cytometry analysis to measure accumulation (EtBr was not present in growing the culture).

Transcription of *acrAB* in SL1344 was growth phase dependent and peaked in early to mid-log phase before decreasing toward stationary phase (Fig. 1), as previously described (18). Previous studies have shown that increased expression of *acrAB* in clinical isolates leads to decreased susceptibility to antibiotics (12). Given the known role of efflux pumps in drug export, one might predict that EtBr accumulation would be lowest when efflux expression was highest. Our data, however, show that this is not the case. In SL1344 cells, accumulation of EtBr was low and remained unchanged across growth despite changes in *acrAB* transcription (Fig. 1). Therefore, changes in efflux pump transcription in different growth phases do not alter levels of accumulation within the cell.

**Growth phase-dependent transcription of *acrAB* does not correlate with intracellular EtBr accumulation, efflux capacity, or AcrAB protein level.** Having shown that *acrAB* transcription does not correlate with ethidium bromide accumulation, the efflux function in a population of cells was measured to determine whether efflux activity varied with growth phase (and *acrAB* expression), even if accumulation did not.

To measure functional efflux capacity of cells, we used the previously described direct efflux activity assay (14), which was further optimized to analyze efflux capacity at three different time points across growth in SL1344. This assay determines the efflux capacity of the cell based on the activity of all efflux pumps (not just AcrAB-TolC) that are able to transport EtBr. Cultures grown for 1, 3, and 5 h had the same capacity for efflux of the substrate, as there was no significant difference in efflux rate between samples taken at each time point (Fig. 2A) (based on time taken for ethidium bromide fluorescence to drop 10%, 25%, and 50% from its maximum fluorescence value) regardless of the different levels of *acrAB* transcription at these time points already established.

Taken together, the low accumulation and similar rate of efflux of EtBr across time in SL1344 suggests that although *acrAB* transcription peaks in mid-exponential phase, activity of the assembled AcrAB-TolC complex remains constant. The AcrB protein is known to be very stable once made, with a predicted half-life of 6 days (26). To measure AcrB protein level at different points during growth, a strain was constructed in which the AcrB protein was tagged with GFP at the C terminus as previously described (27). The generation time and efflux level in this strain were unaffected, confirming that tagging the C terminus of AcrB with GFP did not affect its function. Measurement of GFP fluorescence during 16 h of growth showed that AcrB level remains constant (Fig. 2B). These data suggest that efflux capacity is constant regardless of growth phase



**FIG 2** (A) Time taken for ethidium bromide to be removed from SL1344 cells at 1, 3, and 5 h. Bars represent the time taken for ethidium bromide fluorescence to drop 10%, 25%, and 50% from its original value. Data are based on 3 biological replicates, with error bars showing SEM. Data at 1 h (black), 3 h (dark gray), and 5 h (light gray) are shown. There was no significant difference in the time taken to export EtBr at each time point. (B) GFP/OD<sub>600</sub> from SL1344 AcrB-GFP over 16 h of growth in MOPS minimal medium. This graph shows GFP/OD<sub>600</sub> from AcrB-GFP at the end of lag phase (300 min) until the last time point at 16 h. The dashed black line shows the OD<sub>600</sub>; the green line shows GFP fluorescence (error bars show SEM). SL1344 autofluorescence was subtracted from these data.


due to the constant level of AcrAB protein within a population and may explain why EtBr accumulation remained low in stationary phase despite decreased efflux gene transcription.

#### Intracellular accumulation is dependent on efflux only in actively growing cells.

To further dissect the importance of efflux during different growth stages, we measured EtBr accumulation (as for Fig. 1) in the presence or absence of AcrAB-TolC function (using SL1344  $\Delta$ acrB). The data in Fig. 2 suggest AcrAB-TolC activity is constant; therefore, it was assumed that by removing the efflux pump, EtBr accumulation would be high across growth. When EtBr accumulation in SL1344  $\Delta$ acrB was measured after 1 h of growth, it was 6-fold higher than in SL1344. This is similar to the growth time point used in most other published studies that have shown an increase in accumulation upon deletion of *acrB* (11, 14, 15, 17). However, EtBr accumulation then decreased dramatically and was not significantly different from that of the wild type (WT) from 3 to 6 h of growth (Fig. 3A). This suggests that low accumulation at 1 h in SL1344 greatly depends on efflux to export ethidium bromide from actively growing cells. As there is no significant difference between  $\Delta$ acrB and WT cells from 3 to 6 h, it suggests that AcrAB-TolC is not important in maintaining low accumulation in slower-growing or stationary-phase cells. This is also supported by the *acrAB* expression data, which show highest expression in the early stages of logarithmic growth.

To confirm that low EtBr accumulation in stationary phase was not due to the activity of other RND efflux pumps present in SL1344, EtBr accumulation was also measured in two other mutants of SL1344. In the first, *tolC* was deleted, which compromised most efflux systems in *Salmonella* which use TolC as a common outer membrane channel. The second strain used lacked all four periplasmic adaptor proteins ( $\Delta$ 4PAP;  $\Delta$ acrA  $\Delta$ acrE  $\Delta$ mdsA  $\Delta$ mdtA) and is incapable of assembling any functional RND efflux systems. In both strains, the EtBr accumulation pattern observed recapitulated that seen in SL1344  $\Delta$ acrB, with a peak in accumulation at 1 h but no significant difference from that of SL1344 in stationary-phase cells (Fig. 3B and C). This result showed that low accumulation in stationary phase was not due to any RND pump in SL1344 (or the ABC pump MacAB-TolC). In addition, we also showed that, apart from *acrAB*, whose transcription was highest in mid-log phase and lowest in stationary phase, no other RND pump was actively transcribed under the conditions used to measure accumulation capacity across growth (see Fig. S1 in the supplemental material). For pumps from other families, only *macA* (ABC), *mdfA* (MFS) and *mdtK* (MATE) were transcribed and only at low levels (Fig. S1).

Further investigation into the role of efflux pumps in stationary-phase EtBr accumulation was carried out by measurement in the presence of the proton motive force inhibitor



**FIG 3** EtBr accumulation in SL1344 and SL1344  $\Delta$ *acrB* (A),  $\Delta$ *toIC* (B), and  $\Delta$ 4PAP (C). For each strain, the median EtBr fluorescence per cell in 10,000 single cells was measured every hour between 0 and 6 h of growth for SL1344 (gray circles) and (A) SL1344  $\Delta$ *acrB* (red diamonds), (B) SL1344  $\Delta$ *toIC* (blue hexagons), and (C) SL1344  $\Delta$ 4PAP ( $\Delta$ *acrA*  $\Delta$ *acrE*  $\Delta$ *mdsA*  $\Delta$ *mtdA*) (green triangles). Data from 4 biological replicates for each strain are shown; horizontal bars show means, and error bars show SEM. Median EtBr fluorescence per cell is plotted on the left y axis. Calculated cell numbers per milliliter are plotted on the right y axis with corresponding symbols equating to strain and a dashed line to show growth of the cultures. Cell numbers were based on the mean of the same biological replicates and the same gated population that EtBr fluorescence was measured from. Two-way analysis of variance (ANOVA) and Sidak's multiple-comparison test were carried out for statistical analysis. At 0, 1, and 2 h, EtBr accumulation was significantly increased in  $\Delta$ *acrB* with *P* values of <0.0001 (\*\*\*\*). At 0, 1, 2, and 3 h, EtBr accumulation was significantly increased in SL1344  $\Delta$ *toIC* and SL1344  $\Delta$ 4PAP, with *P* values of <0.0001.



CCCP (carbonyl cyanide *m*-chlorophenylhydrazone). Inhibiting the proton motive force inhibits the activity of the RND, MFS, and MATE pumps of SL1344 (28, 29). In SL1344 in the presence of CCCP, EtBr accumulation peaked at 1 h (Fig. S2). Accumulation levels started to drop in stationary phase, strikingly similar to those in SL1344  $\Delta$ *acrB*, again suggesting that low accumulation in stationary phase is not dependent on RND-, MFS-, or MATE-mediated efflux. This independent confirmation using different mutants and inhibitors demonstrates that the observed low EtBr accumulation in stationary phase is efflux independent.


To investigate whether this was just a *Salmonella* phenomenon, EtBr accumulation was measured in wild-type and a mutant lacking the major RND efflux pump of other Gram-negative bacterial species, including *Escherichia coli* (MG1655 and MG1655  $\Delta$ *acrB*), *Pseudomonas aeruginosa* (PAO1 and PAO1  $\Delta$ *mexA*), and *Klebsiella pneumoniae* (ecl8 and ecl8 *acrB::Gm*). In *E. coli* and *K. pneumoniae*, EtBr accumulation was low throughout growth for the wild type but peaked at 1 h for each *acrB* mutant (Fig. S3), and in *P. aeruginosa*, the *mexA* mutant peaked at 2 h (Fig. S4) and then dropped to WT levels in stationary phase. Therefore, very similar observations are seen in a wide range of Gram-negative organisms.

The EtBr accumulation pattern in *Salmonella* was also shown in MOPS (morpholine-propanesulfonic acid) minimal medium, suggesting that the pattern was not influenced by medium type and specifically was not a result of the limitations of LB (30) (Fig. S5). Even though it is a well-established and -studied model efflux substrate, to counter the possibility that EtBr would give abnormal results which are not representative of other efflux substrates, the same accumulation pattern in *Salmonella* WT and  $\Delta$ *tolC* strains was also shown using the lipophilic dye Nile red (Fig. S6). Unlike EtBr, Nile red fluoresces not on intercalation with DNA but rather when bound to phospholipids or triglycerides (31), showing that this is not an artifact of the dye initially used. Together, these data show that the accumulation pattern described in the absence of efflux is consistent regardless of Gram-negative species, medium type, or efflux substrate used.

**Intracellular accumulation in stationary phase is controlled by reduced membrane permeability.** Together, these data show that cells from later growth phases minimize intracellular accumulation of EtBr (and other substrates) in an efflux-independent manner. We hypothesized this could be due to a shift in the balance between influx and efflux over growth, with influx rate, which is controlled by reduced permeability of the outer membrane, being more important in slower-growing or stationary-phase cells.

Several dyes that are often used to probe the permeability of the outer membrane, such as NPN (1-*N*-phenyl-naphthylamine), are efflux substrates, and therefore, assessing membrane permeability in strains lacking efflux pumps is problematic. Most hydrophilic antibiotics enter Gram-negative bacterial cells through outer membrane porins such as OmpC and OmpF. To investigate whether porins altered the accumulation of EtBr, accumulation assays were performed using the mutants SL1344  $\Delta$ *ompC*  $\Delta$ *ompF*  $\Delta$ *acrB*, SL1344  $\Delta$ *ompC*  $\Delta$ *acrB*, SL1344  $\Delta$ *ompF*  $\Delta$ *acrB*, SL1344  $\Delta$ *ompC*, and SL1344  $\Delta$ *ompF* and showed that none had an EtBr accumulation pattern that was significantly different from those previously seen, confirming that EtBr does not enter *S. Typhimurium* through OmpF or OmpC (Fig. S7). A similar observation was made by Murata et al. in *E. coli* K-12 (32), and they concluded that the OM bilayer is the predominant mode of EtBr entry.

Since SYTO 84 is used in our flow cytometry assay as a probe to stain cells, the accumulation of this dye was first investigated to assess permeability and to determine if it is an efflux substrate. SYTO 84 is marketed as a cell-permeant DNA dye and so is expected to readily enter bacteria. There was no significant difference between the accumulation of SYTO 84 in SL1344 and SL1344  $\Delta$ *acrB*, and in both strains, accumulation peaked after 1 h of growth (Fig. 4). This shows that SYTO 84 is not an efflux substrate and demonstrates the importance of efflux in maintaining low accumulation of drugs and dyes that are substrates in actively growing cells. However, SYTO 84 fluorescence decreased significantly in both strains on entrance to stationary phase (Fig. 4). This suggests that a compound that is not exported via efflux is also less able to enter bacteria




**FIG 4** SYTO 84 accumulation in SL1344 and SL1344  $\Delta acrB$ . Median SYTO 84 fluorescence per cell in 10,000 cells was measured every hour between 0 and 6 h. White circles (SL1344) and blue diamonds ( $\Delta acrB$ ) represent the X-median value of SYTO 84 fluorescence in 10,000 cells within a biological replicate. Four biological replicates for each strain are shown; error bars show SEM. Median SYTO 84 fluorescence is plotted on the left y axis. Calculated cell numbers per milliliter are plotted on the right y axis with corresponding symbols equating to strain and a dashed line to show growth of the culture. Cell numbers were based on the mean of the same biological replicates and the same gated population that EtBr fluorescence was measured from.

during stationary phase, and we hypothesize that this is due to a strengthening of the permeability barrier. It is important to note that, although SYTO 84 fluorescence does decrease around 2.5-fold in stationary phase, the lowest value is still over 45,000 relative fluorescence units (RFU), so the reduction does not compromise its use to differentiate cells from acellular particles in the EtBr accumulation assays using flow cytometry.

Ethidium bromide is a cationic dye that diffuses into cells through the OM (32). LPS molecules on the outer face of the outer membrane are ionically cross-linked to each other by divalent cations ( $Mg^{2+}$  or  $Ca^{2+}$ ) binding to phosphate groups in lipid A, generating a permeability barrier. EDTA is considered a permeabilizer which can chelate and thus displace divalent cations, destabilizing and releasing LPS (33), thereby increasing the permeability of the cell to itself and other compounds (6). Increasing concentrations of EDTA were used to permeabilize the outer membrane and assess the effect on ethidium bromide accumulation (Fig. 5A). Following 1 or 3 h of growth, there was no significant difference in EtBr accumulation up to 100  $\mu M$  EDTA. At 200  $\mu M$  and 500  $\mu M$  EDTA, EtBr accumulation was significantly higher, suggesting that EDTA was able to make the outer membrane more permeable to EtBr. At 5 h, neither 200  $\mu M$  nor 500  $\mu M$  EDTA had any effect on the accumulation of EtBr. This suggests that the *Salmonella* outer membrane is remodeled during entry into stationary phase and becomes less reliant on cation-mediated cross-linking to maintain its permeability barrier to EtBr. Indeed, both *Salmonella* and *E. coli* become more resistant to CAMPs, whose mode of action relies upon interaction with negative charges on the LPS, in stationary phase (34, 35).

A previous study found that increased SDS resistance in carbon-limited stationary-phase *E. coli* is due to decreased envelope permeability mediated by RpoS-dependent and -independent mechanisms (19). The role of RpoS in decreased EtBr permeability in *S. Typhimurium* was therefore investigated by construction of  $\Delta rpoS$  mutants of SL1344 and its  $\Delta acrB$  variant.

Deletion of *rpoS* in SL1344 caused no significant difference in EtBr accumulation (Fig. 5B), although these bacteria were efflux active so EtBr could be pumped out. Comparison of the  $\Delta acrB$  and  $\Delta rpoS \Delta acrB$  mutants (Fig. 5C) revealed a significant difference in EtBr accumulation only around 3 h growth; the  $\Delta rpoS$  mutant showed a delayed decrease in EtBr accumulation, although in stationary phase, the two strains were similar. We conclude that in *S. Typhimurium*, although RpoS might play a role in envelope remodeling, it is not essential for generation of a low-permeability envelope in stationary phase, so there are likely to be RpoS-dependent and -independent pathways to achieve this phenotype. Although SDS and EDTA disrupt the cell envelope in




**FIG 5** (A) EtBr accumulation in SL1344 treated with EDTA. Bars represent median EtBr fluorescence in 10,000 single cells of SL1344. EtBr accumulation was measured in the presence of increasing concentrations of EDTA (0, 1, 10, 100, 200, and 500 mM) from a culture grown for 1 h (black), 3 h (dark blue), and 5 h (light blue). Error bars show SEM from 3 biological replicates. Dashed lines above the bars with asterisks represent significance values based on a *t* test compared to the value when no EDTA was added. At 1 h, treatment with 200 and 500 mM significantly increased EtBr accumulation in SL1344 with *P* values of 0.0013 (\*\*\*) and  $<0.0001$  (\*\*\*\*), respectively. At 3 h, treatment with 200 and 500 mM significantly increased EtBr accumulation in SL1344 with *P* values of 0.0033 (\*\*) and 0.0001 (\*\*\*), respectively. (B and C) EtBr accumulation in SL1344  $\Delta rpoS$  and SL1344  $\Delta acrB \Delta rpoS$ . Four biological replicates for each strain are shown, with a short mean bar and error bars showing SEM. EtBr accumulation is plotted on the left y axis. Calculated cell numbers are plotted on the right y axis. Cell numbers were based on the mean of the same biological replicates and the same gated population that EtBr fluorescence was measured from. (B) SL1344 WT (individual black dots) versus  $\Delta rpoS$  (blue dots). Median EtBr fluorescence per cell in 10,000 SYTO-84<sup>+</sup> flow cytometry events was measured every hour between 0 and 6 h. Individual symbols represent the median value of EtBr fluorescence within a biological replicate. (C) SL1344  $\Delta acrB$  (black diamonds) versus SL1344  $\Delta acrB \Delta rpoS$  (green diamonds). Median EtBr fluorescence per cell in 10,000 SYTO-84<sup>+</sup> flow cytometry events was measured every hour between 0 and 6 h. Individual symbols represent the median value of EtBr fluorescence within a biological replicate. Significant differences to parent strain were measured by a two-way ANOVA and Sidak's multiple-comparison test. At 3 h, EtBr accumulation in SL1344  $\Delta acrB \Delta rpoS$  is significantly different from that in SL1344  $\Delta acrB$  with a *P* value of 0.0002 (\*\*\*).

different ways (detergent disruption of lipid membranes versus chelation of divalent cations), it is clear that RpoS-dependent and -independent mechanisms play a role in envelope remodeling in both *E. coli* (19) and *S. Typhimurium*.

**RNA-seq analysis identified several pathways likely to be involved in reduced envelope permeability in *S. Typhimurium*.** Given that the data above did not identify a definitive mechanism by which the stationary-phase cell envelope displays lower permeability to EtBr, we used RNA-seq analysis to identify genes and pathways that may be involved in changes to Gram-negative cells as they enter stationary phase. Growing cultures of SL1344 were sampled after 1 h, 3 h, and 5 h of growth, and RNA was extracted and analyzed by GENEWIZ, Inc. Comparing SL1344 at 1 h versus 3 or 5 h of growth, 1,228 (26%) and 2,260 (47%) genes were differentially expressed, respectively. Differentially expressed genes were then identified that encode proteins involved in envelope remodeling in stationary phase, many of which have been shown to increase barrier function (Table S2; summarized in Fig. 6).

Previous studies have suggested that multiple layers of the cell envelope are remodeled upon entry into stationary phase (34), and our RNA-seq data support this; a full description of this data set is in the supplemental material. Inner membrane fluidity decreases with cyclopropane fatty acid incorporation (36–38), mediated by upregulation of *cfa*. Stationary-phase peptidoglycan contains 3-3 (LD) rather than 4-3 (DD) cross-links (22, 39, 40); relevant transpeptidases are up- and downregulated. The quantity of Lpp in the OM increases (*lppB* is upregulated), and Lpp becomes more highly cross-linked to the PG (*ldeE* is upregulated [22]), which has been shown to increase barrier function (41). OM





**FIG 6** Model showing that the differentially expressed genes identified in the RNA-seq encode proteins involved in envelope remodeling in stationary phase to increase barrier function. Green text represents genes with increased expression, and red text represents genes with decreased expression.

inner leaflet cardiolipin content is known to increase (42) potentially mediated by upregulation of *clsB*. LPS modification pathways important in exponential phase (e.g., the *pmr* genes, which confer CAMP resistance primarily through negative-charge neutralization) (43–45), are downregulated, whereas *lpxO* (involved in myristoyl chain hydroxylation and implicated in CAMP resistance in *K. pneumoniae* [46]) is upregulated. Genes involved in O-antigen synthesis and chain length regulation are downregulated; average O-antigen chain length increases in stationary phase, and O-antigen structure has been shown to influence serum resistance (47) and CAMP susceptibility (48). Finally, genes involved in enterobacterial common antigen (ECA) synthesis are downregulated; ECA is implicated in envelope integrity and bile resistance.

Taken together, these observations lead to a model (Fig. 6) suggesting why the exponential-phase cell envelope is more susceptible to attack from various factors (EtBr, CAMPs, EDTA, and antibiotics). Resistance to self-mediated uptake in exponential phase is provided primarily by the barrier function of LPS, comprising lipid hydrophobicity and cross-linking between phosphate groups and divalent cations. The LPS takes the burden because the inner layers of the envelope (peptidoglycan [PG] and the inner membrane [IM]) are by necessity more fluid; PG is extensively and continually remodeled to permit growth and division, and the IM is similarly fluid. The reliance on the LPS as the primary barrier poses problems when antimicrobials such as EDTA and CAMPs target the phosphate-cation bridges. The cell responds by shielding negative charges and modifying the LPS lipid content to decrease fluidity, regulated by PmrAB.

In stationary phase, each layer of the envelope plays a greater role in barrier function because remodeling and fluidity are less of a requirement. The lipid components of the IM and OM become less fluid, and the PG contains more LD cross-links and becomes more cross-linked to the OM, further strengthening the OM permeability barrier and decreasing (but not eliminating) the requirement for cation cross-linking of LPS. The saccharide components of the LPS provide the outermost layer of protection. This "laminated" approach shares the burden of protection and generates a strong barrier against multiple chemicals which seek to enter and damage the cell, reflected by the increased resistance of stationary-phase cells to multiple stressors.

## DISCUSSION

This study shows that the mechanisms that control drug accumulation are growth phase dependent. In actively growing cells, efflux is fundamental to maintaining low

EtBr accumulation and subsequently survival of the bacterial population. Bacterial infections are complex, and bacterial populations will often not be in a single growth phase; therefore, careful consideration may be required for the most effective antibiotic treatment. We have shown that stationary-phase slow-growing or nongrowing cells are impermeable and that this is due not to changes in porin production but to membrane remodeling and increased peptidoglycan cross-linking, which reinforces the envelope barrier function.

The direct effect of these growth phase-dependent changes on susceptibility to antimicrobials is difficult to determine, as most MIC assays are growth based and take many hours, meaning that they are not sensitive enough to detect the effects of differences in intracellular antibiotic accumulation. In addition, they usually measure only one aspect of viability: the ability of bacteria to grow on an agar plate. This also means that bacteria with a viable-but-nonculturable (VBNC) phenotype cannot be detected. Future work will investigate antibiotic susceptibility in different growth phases in a non-growth-dependent manner.

However, our findings indicate that the treatment of chronic infections and biofilms where bacterial cells are slow growing or nongrowing may need to be considered more carefully. Successful treatment of these infections is already extremely difficult, and careful consideration is already made for treatment of intrinsically impermeable pathogens such as *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. More extensive research into the effects of an impermeable membrane on treatment during infection must now be carried out.

Our findings also have implications for the development and use of efflux inhibitors. Efflux pumps are important in maintaining low accumulation only in actively growing cells, which have a more permeable envelope. If an infecting organism is actively growing, it seems likely that efflux inhibitors would be effective at increasing the accumulation of antibiotics within cells to potentiate their activity. However, if cells are in a slow-growing or nongrowing state, where membrane permeability is fundamental to maintaining low drug accumulation, efflux inhibitors may not be an effective treatment option. It is also possible that administering an efflux inhibitor where it has no effect on treating an infection may also lead to the development of new mechanisms of antimicrobial resistance.

## MATERIALS AND METHODS

**Strains and growth conditions.** Unless otherwise stated, all experiments used *Salmonella enterica* serovar Typhimurium SL1344 (49). The  $\Delta acrB$  and  $\Delta 4PAP$  ( $\Delta acrA \Delta acrE \Delta mdsA \Delta mdtA$ ) strains were described previously (50, 51). SL1344  $\Delta ompF$  and  $\Delta ompC$  strains were constructed for this study using the Datsenko and Wanner method of gene deletion (52). Transcriptional reporter constructs were made by fusing the promoter of each efflux pump gene to the GFP gene in the pMW82 plasmid (53). These plasmids were transformed into SL1344 and SL1344  $\Delta acrB$ . *E. coli* MG1655  $\Delta acrB$  (15), *P. aeruginosa* PAO1  $\Delta mexA$  (54), and *K. pneumoniae* e18  $acrB::Gm$  (17) were also used as part of this study and were described previously. All oligonucleotides are listed in Table S1.

Unless otherwise stated, LB (Sigma) was used as the growth medium for all assays. One assay used MOPS minimal medium (Teknova), which was supplemented with 400 mg/liter histidine.

**Chromosomal insertion of *gfp* downstream of *acrB* to produce SL1344 AcrB-GFP.** To measure the protein level of AcrB in *S. Typhimurium*, a gene encoding a monomeric superfolder GFP (msfGFP) was inserted downstream of *acrB* on the chromosome to produce an AcrB-msfGFP fusion protein. This strain was created using the msfGFP from the pET GFP LIC cloning vector (u-msfGFP), which was a gift from Scott Gradia (Addgene plasmid number 29772; <http://n2t.net/addgene:29772>; RRID, Addgene\_29772). Strain construction was based on the method used by Bergmiller et al. in *E. coli* (27) where the codon-optimized polylinker was used. Using restriction and ligation, the *aph* gene was inserted into pET LIC vector (u-msfGFP), so that strains containing the plasmid could be selected for. Using this plasmid as the template, *gfp* and *aph* were inserted into the chromosome downstream of *acrB* in SL1344 to produce a protein fusion strain.

**Flow cytometry assay.** The flow-cytometric EtBr accumulation assay was described previously (17). Here, this method was used to measure accumulation in samples from the same culture at different time points during batch culture. Briefly, cultures were grown at 37°C overnight in 5 ml of LB and subcultured at 4% into fresh LB. A sample was taken at 0 h and then every hour for 6 h during growth. At each hour, sample volume was adjusted such that approximately  $10^7$  cells were harvested and resuspended in  $1 \times$  HEPES-buffered saline ( $5 \times$  HBS; Alfa Aesar). Cells were washed and resuspended in 1 ml HBS. One hundred microliters of cell suspension was then further diluted into 500  $\mu$ l HBS and SYTO 84 (Thermo

Fisher Scientific) and ethidium bromide added to give final concentrations of 10  $\mu\text{M}$  and 100  $\mu\text{M}$ , respectively. Samples were incubated for 10 min before measuring accumulation by flow cytometry. Flow cytometry settings and emission filters described by Whittle et al. (17) were used. Briefly, the SYTO 84 fluorescence emission was collected in the YL1-H channel (585/16 nm) using a 561-nm yellow laser and used to differentiate cells from acellular material. EtBr fluorescence was collected using the BL3-H channel (695/40 nm) using a 488-nm blue laser. SYTO 84 accumulation measurements (Fig. 4) were not obtained in a repeated experiment, but data were reanalyzed from EtBr accumulation assays, and therefore fluorescence emission was collected in the YL1-H channel (585/16 nm) using a 561-nm yellow laser. Nile red accumulation was measured as previously described (17). In these experiments SYTO 9 (10  $\mu\text{M}$ ; Thermo Fisher Scientific) was used to differentiate cells from acellular particles using the BL2-H channel. Nile red has an excitation wavelength of 549 nm and an emission wavelength of 628 nm in the presence of phospholipids, and in a neutral lipid environment (triglycerides), the fluorescence shifts to excitation/emission of 510/580 nm (31). Nile red fluorescence was excited using the yellow laser and detected using the YL1-H channel for orange fluorescence (17).

**Flow cytometry assay in the presence of EDTA.** Growing culture samples were taken at 1, 3, and 5 h as described above. Samples were made with various concentrations of EDTA (0  $\mu\text{M}$ , 1  $\mu\text{M}$ , 10  $\mu\text{M}$ , 100  $\mu\text{M}$ , 200  $\mu\text{M}$ , and 500  $\mu\text{M}$ ) in 500  $\mu\text{l}$  HBS. These concentrations of EDTA increased the final volume of the sample because the stock concentration was limited by solubility. Dyes were then added, but the volume added was adjusted to maintain the final concentrations stated above. Once the dyes were added, 100  $\mu\text{l}$  of cell suspension was added and cells were incubated for 10 min at room temperature. Samples were then analyzed by flow cytometry.

**Whole-population transcription analysis.** Overnight cultures containing pMW82 transcriptional reporter plasmids were diluted 1:10,000 in MOPS minimal medium, supplemented with 50  $\mu\text{g/ml}$  ampicillin. Optical density at 600 nm ( $\text{OD}_{600}$ ) and GFP fluorescence were measured every 30 min for 12 h using a Fluostar Omega (BMG Labtech) incubated at 37°C.  $\text{OD}_{600}$  and GFP fluorescence were measured, and values for a minimal-medium-only control were subtracted from the data. SL1344 autofluorescence was removed by subtracting SL1344 fluorescence from that of pMW82 strains. GFP fluorescence divided by  $\text{OD}_{600}$  was used as a measurement to disregard cell density across growth.

**Efflux assay.** Efflux assays were carried out as previously described (14). This assay measures direct efflux activity of a population of cells by preloading cells with a fluorescent efflux substrate in the presence of the proton motive force inhibitor, CCCP, and re-energizing cells with glucose to measure the decrease in fluorescence as substrates leave the cells. Briefly, overnight cultures of SL1344 and SL1344  $\Delta\text{acrB}$  were subcultured into fresh LB and then grown for 5 h at 37°C. At 1, 3, and 5 h, 10 ml of culture was taken and the  $\text{OD}_{600}$  measured. The harvested cell pellet was then resuspended in phosphate buffer containing  $\text{MgCl}_2$  buffer, and each strain was adjusted to the same  $\text{OD}_{600}$ .

**RNA-seq.** The transcriptomes of SL1344 and SL1344  $\Delta\text{acrB}$  were analyzed at different time points during growth (1, 3, and 5 h). There were 4 replicates of each strain. MOPS minimal medium was inoculated at 4% with overnight cultures. Cultures were incubated at 37°C with shaking for 5 h. At 1 h, 5 ml of culture was centrifuged at  $3,500 \times g$  for 5 min at room temperature to harvest the cells. The supernatant was removed and the pellet was snap-frozen. At 3 and 5 h, only 1 ml of culture was harvested and snap-frozen. GENEWIZ, Inc., carried out the RNA extraction, quality control, library preparation, sequencing, and bioinformatic analysis. Briefly, total RNA was extracted from *S. Typhimurium* cell pellets using an RNeasy Plus universal kit (Qiagen), and RNA quality control was carried out using a Qubit 2.0 fluorometer to measure total RNA concentration and an Agilent TapeStation to produce an RNA integrity number (RIN) and a DV200 score. To remove rRNA, the Ribozero removal kit was used (Illumina). The NEBNext Ultra II RNA library preparation kit (Illumina) was used for library preparation, following the manufacturer's protocol. For library preparation, cDNA was synthesized, end repaired, and adenylated at the 3' ends. Universal adapters were ligated to cDNA, and library enrichment was carried out using limited-cycle PCR. Sequencing was carried out using Illumina HiSeq 4000. Bioinformatic data analysis was carried out by GENEWIZ, Inc. Trimmed reads were mapped to the SL1344 reference genome [FQ312003](#) using the Bowtie2 aligner. Unique gene hit counts were calculated by using featureCounts from the Subread package. All statistical analysis was performed using R. With the package DESeq2, a comparison of gene expression between the groups of samples was performed. The Wald test was used to generate *P* values and  $\log_2$  fold changes.

**Data availability.** The data have been deposited with ArrayExpress (accession no. E-MTAB-9679).

## SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

**TEXT S1**, DOCX file, 0.1 MB.

**FIG S1**, TIF file, 0.2 MB.

**FIG S2**, TIF file, 0.1 MB.

**FIG S3**, TIF file, 0.2 MB.

**FIG S4**, TIF file, 0.1 MB.

**FIG S5**, TIF file, 0.1 MB.

**FIG S6**, TIF file, 0.1 MB.

**FIG S7**, TIF file, 0.1 MB.

**TABLE S1**, DOCX file, 0.01 MB.

**TABLE S2**, DOCX file, 0.02 MB.

## ACKNOWLEDGMENTS

We declare that the research was conducted in the absence of any commercial or financial relationships that might be considered a conflict of interest.

J.M.A.B., T.W.O., and E.E.W. designed the assays. GFP transcriptional reporter strains were constructed by E.T. E.E.W. and H.E.M. performed experiments to obtain samples for RNA-seq. E.E.W. performed all other experiments. E.E.W. analyzed all data. RNA-seq data were analyzed by E.E.W. and T.W.O. The manuscript was written by E.E.W., J.M.A.B., T.W.O., and M.W.

E.E.W. was funded by AAMR Wellcome Trust DTP grant 108876/B/15/Z at the University of Birmingham. J.M.A.B. and H.M. were funded by BBSRC grant BB/M02623X/1 (David Phillips Fellowship to J.M.A.B.).

## REFERENCES

- Nikaido H. 1989. Outer membrane barrier as a mechanism of antimicrobial resistance. *Antimicrob Agents Chemother* 33:1831–1836. <https://doi.org/10.1128/AAC.33.11.1831>.
- Pratt LA, Hsing W, Gibson KE, Silhavy TJ. 1996. From acids to osmZ: multiple factors influence synthesis of the OmpF and OmpC porins in *Escherichia coli*. *Mol Microbiol* 20:911–917. <https://doi.org/10.1111/j.1365-2958.1996.tb02532.x>.
- Dupont H, Choinier P, Roche D, Adiba S, Sookdeb M, Branger C, Denamur E, Mammeri H. 2017. Structural alteration of OmpR as a source of ertapenem resistance in a CTX-M-15-producing *Escherichia coli* O25b:H4 sequence type 131 clinical isolate. *Antimicrob Agents Chemother* 61:e00014-17. <https://doi.org/10.1128/AAC.00014-17>.
- Dé E, Baslé A, Jaquinod M, Saint N, Malléa M, Molle G, Pagès JM. 2001. A new mechanism of antibiotic resistance in Enterobacteriaceae induced by a structural modification of the major porin. *Mol Microbiol* 41:189–198. <https://doi.org/10.1046/j.1365-2958.2001.02501.x>.
- Bajaj H, Scorciapino MA, Moynie L, Page MGP, Naismith JH, Ceccarelli M, Winterhalter M. 2016. Molecular basis of filtering carbapenems by porins from  $\beta$ -lactam-resistant clinical strains of *Escherichia coli*. *J Biol Chem* 291:2837–2847. <https://doi.org/10.1074/jbc.M115.690156>.
- Hancock REW, Bell A. 1988. Antibiotic uptake into gram-negative bacteria. *Eur J Clin Microbiol Infect Dis* 7:713–720. <https://doi.org/10.1007/BF01975036>.
- Hancock REW, Raffle VJ, Nicas TI. 1981. Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 19:777–785. <https://doi.org/10.1128/AAC.19.5.777>.
- Delcour AH. 2009. Outer membrane permeability and antibiotic resistance. *Biochim Biophys Acta* 1794:808–816. <https://doi.org/10.1016/j.bbapap.2008.11.005>.
- Hancock RE. 1984. Alterations in outer membrane permeability. *Annu Rev Microbiol* 38:237–264. <https://doi.org/10.1146/annurev.mi.38.100184.001321>.
- Hassan KA, Liu Q, Elbourne LDH, Ahmad I, Sharples D, Naidu V, Chan CL, Li L, Harborne SPD, Pokhrel A, Postis VLG, Goldman A, Henderson PJF, Paulsen IT. 2018. Pacing across the membrane: the novel PACE family of efflux pumps is widespread in Gram-negative pathogens. *Res Microbiol* 169:450–454. <https://doi.org/10.1016/j.resmic.2018.01.001>.
- Blair JMA, Smith HE, Ricci V, Lawler AJ, Thompson LJ, Piddock LJV. 2015. Expression of homologous RND efflux pump genes is dependent upon AcrB expression: implications for efflux and virulence inhibitor design. *J Antimicrob Chemother* 70:424–431. <https://doi.org/10.1093/jac/dku380>.
- Webber MA, Piddock LJV. 2001. Absence of mutations in marRAB or soxRS in acrB-overexpressing fluoroquinolone-resistant clinical and veterinary isolates of *Escherichia coli*. *Antimicrob Agents Chemother* 45:1550–1552. <https://doi.org/10.1128/AAC.45.5.1550-1552.2001>.
- Chowdhury N, Suhani S, Purkaystha A, Begum MK, Raihan T, Alam MJ, Islam K, Azad AK. 2019. Identification of AcrAB-TolC efflux pump genes and detection of mutation in efflux repressor AcrR from omeprazole responsive multidrug-resistant *Escherichia coli* isolates causing urinary tract infections. *Microbiol Insights* 12:1178636119889629–1178636119889610. <https://doi.org/10.1177/1178636119889629>.
- Smith HE, Blair JMA. 2014. Redundancy in the periplasmic adaptor proteins AcrA and AcrE provides resilience and an ability to export substrates of multidrug efflux. *J Antimicrob Chemother* 69:982–987. <https://doi.org/10.1093/jac/dkt481>.
- Wang-Kan X, Blair JMA, Chirullo B, Betts J, La Ragione RM, Ivans A, Ricci V, Opperman TJ, Piddock LJV. 2017. Lack of AcrB efflux function confers loss of virulence on *Salmonella enterica* serovar typhimurium. *mBio* 8:e00968-17. <https://doi.org/10.1128/mBio.00968-17>.
- Blair JMA, Piddock LJV. 2016. How to measure export via bacterial multidrug resistance efflux pumps. *mBio* 7:e00840-16. <https://doi.org/10.1128/mBio.00840-16>.
- Whittle EE, Legood SW, Alav I, Dulyayangkul P, Overton TW, Blair JMA. 2019. Flow cytometric analysis of efflux by dye accumulation. *Front Microbiol* 10:2319. <https://doi.org/10.3389/fmicb.2019.02319>.
- Bailey AM, Webber MA, Piddock LJV. 2006. Medium plays a role in determining expression of acrB, marA, and soxS in *Escherichia coli*. *Antimicrob Agents Chemother* 50:1071–1074. <https://doi.org/10.1128/AAC.50.3.1071-1074.2006>.
- Mitchell AM, Wang W, Silhavy TJ. 2017. Novel RpoS-dependent mechanisms strengthen the envelope permeability barrier during stationary phase. *J Bacteriol* 199:e00708-16. <https://doi.org/10.1128/JB.00708-16>.
- Allen RJ, Scott GK. 1979. Biosynthesis and turnover of outer-membrane proteins in *Escherichia coli* ML308-225. *Biochem J* 182:407–412. <https://doi.org/10.1042/bj1820407>.
- Wensink J, Gilden N, Witholt B. 1982. Attachment of lipoprotein to the murein of *Escherichia coli*. *Eur J Biochem* 122:587–590. <https://doi.org/10.1111/j.1432-1033.1982.tb06479.x>.
- Glauner B, Holtje JV, Schwarz U. 1988. The composition of the murein of *Escherichia coli*. *J Biol Chem* 263:10088–10095. [https://doi.org/10.1016/S0021-9258\(19\)81481-3](https://doi.org/10.1016/S0021-9258(19)81481-3).
- El-Khani MA, Stretton RJ. 1981. Effect of growth medium on the lipid composition of log and stationary phase cultures of *Salmonella typhimurium*. *Microbios* 31:161–169.
- Grogan DW, Cronan JE. 1997. Cyclopropane ring formation in membrane lipids of bacteria. *Microbiol Mol Biol Rev* 61:429–441. <https://doi.org/10.1128/mmb.61.4.429-441.1997>.
- Mengin-Lecreux D, Van Heijenoort J. 1985. Effect of growth conditions on peptidoglycan content and cytoplasmic steps of its biosynthesis in *Escherichia coli*. *J Bacteriol* 163:208–212. <https://doi.org/10.1128/jb.163.1.208-212.1985>.
- Chai Q, Webb SR, Wang Z, Dutch RE, Wei Y. 2016. Study of the degradation of a multidrug transporter using a non-radioactive pulse chase method. *Anal Bioanal Chem* 408:7745–7751. <https://doi.org/10.1007/s00216-016-9871-7>.
- Bergmiller T, Andersson AMC, Tomasek K, Balleza E, Kiviet DJ, Hauschild R, Tkačik G, Guet CC. 2017. Biased partitioning of the multidrug efflux pump AcrAB-TolC underlies long-lived phenotypic heterogeneity. *Science* 356:311–315. <https://doi.org/10.1126/science.aaf4762>.
- Pagès JM, Amaral L. 2009. Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. *Biochim Biophys Acta* 1794:826–833. <https://doi.org/10.1016/j.bbapap.2008.12.011>.
- Pagès JM, Masi M, Barbe J. 2005. Inhibitors of efflux pumps in Gram-negative bacteria. *Trends Mol Med* 11:382–389. <https://doi.org/10.1016/j.molmed.2005.06.006>.



30. Nikaido H. 2009. The limitations of LB medium. Small Things Considered. <https://schaechter.asmblog.org/schaechter/2009/11/the-limitations-of-lb-medium.html>.
31. Greenspan P, Fowler SD. 1985. Spectrofluorometric studies of the lipid probe, Nile red. *J Lipid Res* 26:781–789. [https://doi.org/10.1016/S0022-2275\(20\)34307-8](https://doi.org/10.1016/S0022-2275(20)34307-8).
32. Murata T, Tseng W, Guina T, Miller SJ, Nikaido H. 2007. PhoPQ-mediated regulation produces a more robust permeability barrier in the outer membrane of *Salmonella enterica* serovar typhimurium. *J Bacteriol* 189:7213–7222. <https://doi.org/10.1128/JB.00973-07>.
33. Leive L. 1965. Release of lipopolysaccharide by EDTA treatment of *E. coli*. *Biochem Biophys Res Commun* 21:290–296. [https://doi.org/10.1016/0006-291x\(65\)90191-9](https://doi.org/10.1016/0006-291x(65)90191-9).
34. McLeod GI, Spector MP. 1996. Starvation- and stationary-phase-induced resistance to the antimicrobial peptide polymyxin B in *Salmonella typhimurium* is RpoS ( $\sigma^S$ ) independent and occurs through both PhoP-dependent and -independent pathways. *J Bacteriol* 178:3683–3688. <https://doi.org/10.1128/jb.178.13.3683-3688.1996>.
35. Agrawal A, Rangarajan N, Weisshaar JC. 2019. Resistance of early stationary phase *E. coli* to membrane permeabilization by the antimicrobial peptide Cecropin A. *Biochim Biophys Acta Biomembr* 1861:182990. <https://doi.org/10.1016/j.bbamem.2019.05.012>.
36. Bianco CM, Fröhlich KS, Vanderpool CK. 2019. Bacterial cyclopropane fatty acid synthase mRNA is targeted by activating and repressing small RNAs. *J Bacteriol* 201:e00461-19. <https://doi.org/10.1128/JB.00461-19>.
37. Qi Y, Liu H, Chen X, Liu L. 2019. Engineering microbial membranes to increase stress tolerance of industrial strains. *Metab Eng* 53:24–34. <https://doi.org/10.1016/j.ymben.2018.12.010>.
38. Huisman GW, Siegele DA, Zambrano MM, Kolter R. 1996. Morphological and physiological changes during stationary phase, p 1672–1682. In Neidhardt FC, Curtiss R, III, Ingraham JL, Lin ECC, Low KB, Magasanik B, Reznikoff WS, Riley M, Schaechter M, Umberger HE (ed.), *Escherichia coli and Salmonella: cellular and molecular biology*, 2nd ed. ASM Press, Washington, DC.
39. Morè N, Martorana AM, Biboy J, Otten C, Winkle M, Serrano CKG, Montón Silva A, Atkinson L, Yau H, Breukink E, den Blaauwen T, Vollmer W, Polissi A. 2019. Peptidoglycan remodeling enables *Escherichia coli* to survive severe outer membrane assembly defect. *mBio* 10:e02729-18. <https://doi.org/10.1128/mBio.02729-18>.
40. Magnet S, Dubost L, Marie A, Arthur M, Gutmann L. 2008. Identification of the L,D-transpeptidases for peptidoglycan cross-linking in *Escherichia coli*. *J Bacteriol* 190:4782–4785. <https://doi.org/10.1128/JB.00025-08>.
41. Peters K, Pazos M, Edoos Z, Hugonnet JE, Martorana AM, Polissi A, VanNieuwenhze MS, Arthur M, Vollmer W. 2018. Copper inhibits peptidoglycan LD-transpeptidases suppressing  $\beta$ -lactam resistance due to bypass of penicillin-binding proteins. *Proc Natl Acad Sci U S A* 115:10786–10791. <https://doi.org/10.1073/pnas.1809285115>.
42. Hiraoka S, Matsuzaki H, Shibuya I. 1993. Active increase in cardiolipin synthesis in the stationary growth phase and its physiological significance in *Escherichia coli*. *FEBS Lett* 336:221–983. [https://doi.org/10.1016/0014-5793\(93\)80807-7](https://doi.org/10.1016/0014-5793(93)80807-7).
43. Raetz CRH, Reynolds CM, Trent MS, Bishop RE. 2007. Lipid modification systems in gram-negative bacteria. *Annu Rev Biochem* 76:295–329. <https://doi.org/10.1146/annurev.biochem.76.010307.145803>.
44. May JF, Groisman EA. 2013. Conflicting roles for a cell surface modification in *Salmonella*. *Mol Microbiol* 88:970–983. <https://doi.org/10.1111/mmi.12236>.
45. Agrawal A, Weisshaar JC. 2018. Effects of alterations of the *E. coli* lipopolysaccharide layer on membrane permeabilization events induced by Cecropin A. *Biochim Biophys Acta Biomembr* 1860:1470–1479. <https://doi.org/10.1016/j.bbamem.2018.04.009>.
46. Llobet E, Martínez-Moliner V, Moranta D, Dahlström KM, Regueiro V, Tomás A, Cano V, Pérez-Gutiérrez C, Frank CG, Fernández-Carrasco H, Insua JL, Salminen TA, Garmendia J, Bengoechea JA. 2015. Deciphering tissue-induced *Klebsiella pneumoniae* lipid structure. *Proc Natl Acad Sci U S A* 112:E6369–E6378. <https://doi.org/10.1073/pnas.1508820112>.
47. Bravo D, Silva C, Carter JA, Hoare A, Álvarez SA, Blondel CJ, Zaldivar M, Valvano MA, Contreras I. 2008. Growth-phase regulation of lipopolysaccharide O-antigen chain length influences serum resistance in serovars of *Salmonella*. *J Med Microbiol* 57:938–946. <https://doi.org/10.1099/jmm.0.47848-0>.
48. Ricci V, Zhang D, Teale C, Piddock LJV. 2020. The O-antigen epitope governs susceptibility to colistin in *Salmonella enterica*. *mBio* 11:e02831-19. <https://doi.org/10.1128/mBio.02831-19>.
49. Brenner FW, Villar RG, Angulo FJ, Tauxe R, Swaminathan B. 2000. *Salmonella* nomenclature. *J Clin Microbiol* 38:2465–2467. <https://doi.org/10.1128/JCM.38.7.2465-2467.2000>.
50. Eaves DJ, Ricci V, Piddock LJV. 2004. Expression of *acrB*, *acrF*, *acrD*, *marA*, and *soxS* in *Salmonella enterica* serovar Typhimurium: role in multiple antibiotic resistance. *Antimicrob Agents Chemother* 48:1145–1150. <https://doi.org/10.1128/AAC.48.4.1145-1150.2004>.
51. McNeil HE, Alav I, Torres RC, Rossiter AE, Laycock E, Legood S, Kaur I, Davies M, Wand M, Webber MA, Bavro VN, Blair JMA. 2019. Identification of binding residues between periplasmic adapter protein (PAP) and RND efflux pumps explains PAP-pump promiscuity and roles in antimicrobial resistance. *PLoS Pathog* 15:e1008101. <https://doi.org/10.1371/journal.ppat.1008101>.
52. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci U S A* 97:6640–6645. <https://doi.org/10.1073/pnas.120163297>.
53. Bumann D, Valdivia RH. 2007. Identification of host-induced pathogen genes by differential fluorescence induction reporter systems. *Nat Protoc* 2:770–777. <https://doi.org/10.1038/nprot.2007.78>.
54. Held K, Ramage E, Jacobs M, Gallagher L, Manoil C. 2012. Sequence-verified two-allele transposon mutant library for *Pseudomonas aeruginosa* PAO1. *J Bacteriol* 194:6387–6389. <https://doi.org/10.1128/JB.01479-12>.